摘要
目的探讨血清趋化因子配体5(CXCL5)对膀胱癌患者外科治疗后复发的影响。方法选取收治的外科手术治疗的膀胱癌患者96例为研究对象,采用酶联免疫吸附法(ELISA),检测其中血清CXCL5水平,将CXCL5≤700pg/ml定义为阴性,CXCL5>700 pg/ml定义为阳性。结果 96例膀胱癌患者中CXCL5阳性者30例,占31.25%。CXCL5水平与TNM分期、病理类型、组织学分级和淋巴结转移相关(P<0.05),与年龄、性别、肿瘤大小无关(P>0.05)。CXCL5阳性和CXCL5阴性患者无瘤生存时间分别为41.5个月和55.2个月,5年无瘤生存率分别为26.67%(8/30)和57.58%(38/66),差异有统计学意义(P<0.05)。多变量COX回归分析表明:TNM分期、病理类型、淋巴结转移和CXCL5是膀胱癌患者术后复发的独立预测因素。结论膀胱癌患者血清CXCL5基线水平不但可以作为初步评估病情严重程度的指标,还可以作为术后复发的独立预测指标。
Objective To investigate the effect of serum chemokine ligand 5（ CXCL5） on the recurrence of bladder cancer patients after surgical treatment. Methods 96 patients with bladder cancer who underwent surgical treatment were enrolled in this study. General information,including gender,age,contact telephone and so on were collected. Before treatment,fasting blood samples were collected to detect CXCL5 with enzyme-linked immunosorbent assay（ ELISA）. CXCL5 ≤700 pg/ml was defined as negative and CXCL5 700 pg/ml was defined as positive. Follow-up using telephone. Results Among the 96 patients with bladder cancer,30 were CXCL5 positive,accounting for 31. 25%. The level of CXCL5 was correlated with TNM stage,pathological type,histological grade and lymph node metastasis（ P〈0. 05）,but not with age,sex and tumor size（ P〈0. 05）. The survival time of CXCL5 positive and CXCL5 negative patients were 41. 5 months and 55. 2 months respectively. 5-year disease-free survival rates were 26. 67%（ 8/30） and 57. 58%（ 38/66） respectively,the difference was statistically significant（ P〈0. 05）.Multivariate COX regression analysis showed that TNM staging,pathological type,lymph node metastasis and CXCL5 were independent predictors of postoperative recurrence of bladder cancer patients. Conclusion The level of serum CXCL5 in bladder cancer patients can not only be used as an index to evaluate the severity of the disease,but also as an independent predictor of postoperative recurrence.
出处
《实用癌症杂志》
2017年第9期1444-1446,共3页
The Practical Journal of Cancer
